...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and biological evaluation of novel 5-(hydroxamic acid) methyl oxazolidinone derivatives
【24h】

Synthesis and biological evaluation of novel 5-(hydroxamic acid) methyl oxazolidinone derivatives

机译:新型5-(异羟肟酸)甲基恶唑烷酮衍生物的合成及生物学评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Research activities on the oxazolidinone antibacterial class of compounds continue to focus on developing newer derivatives with improved potency, broad-spectrum activity and safety profiles superior to linezolid. Among the safety concerns with the oxazolidinone antibacterial agents is inhibition of monoamine oxidases (MAO) resulting from their structural similarity with toloxatone, a known MAO inhibitor. Diverse substitution patterns at the C-5 position of the oxazolidinone ring have been shown to significantly affect both antibacterial activity and MAO inhibition to varying degrees. Also, the antibacterial activity of compounds containing iron-chelating functionalities, such as the hydroxamic acids, 8-hydroxyquinolines and catechols have been correlated to their ability to alter iron intake and/or metabolism. Hence a series of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives were synthesized and evaluated for their antibacterial and MAO-A and -B inhibitory activities. The compounds were devoid of significant antibacterial activity but most demonstrated moderate MAO-A and -B inhibitory activities. Computer modeling studies revealed that the lack of potent antibacterial activity was due to significant steric interaction between the hydroxamic acid N-OH oxygen atom and one of the G2540 5'-phosphate oxygen atoms at the bacterial ribosomal binding site. Therefore, the replacement of the 5-acetamidomethyl group of linezolid with the 5-(N-hydroxyacetamido)methyl group present in the hydroxamic acid oxazolidinone derivatives was concluded to be detrimental to antibacterial activity. Furthermore, the 5-(hydroxamic acid)methyl oxazolidinone derivatives were also less active as MAO-A and -B inhibitors compared with linezolid and the selective inhibitors clorgyline and pargyline. In general, the 5-(hydroxamic acid)methyl oxazolidinone derivatives demonstrated moderate but selective MAO-B inhibitory activity. (C) 2015 Elsevier Masson SAS. All rights reserved.
机译:对恶唑烷酮类抗菌化合物的研究活动继续集中在开发具有更高效能,广谱活性和优于利奈唑胺的安全性的新型衍生物。恶唑烷酮类抗菌剂的安全性问题之一是对单胺氧化酶(MAO)的抑制,这是由于它们与已知的MAO抑制剂toloxatone具有结构相似性。已显示恶唑烷酮环的C-5位置的不同取代方式在不同程度上显着影响抗菌活性和MAO抑制作用。同样,含有铁螯合功能的化合物(例如异羟肟酸,8-羟基喹啉和儿茶酚)的抗菌活性也与它们改变铁摄入和/或代谢的能力有关。因此,合成了一系列新颖的5-(异羟肟酸)甲基恶唑烷酮衍生物,并对其抗菌和MAO-A和-B抑制活性进行了评估。该化合物没有明显的抗菌活性,但大多数显示出中等的MAO-A和-B抑制活性。计算机建模研究表明,缺乏有效的抗菌活性是由于异羟肟酸N-OH氧原子与细菌核糖体结合位点的G2540 5'-磷酸氧原子之一之间存在显着的空间相互作用。因此,结论是异羟肟酸恶唑烷酮衍生物中存在的5-(N-羟基乙酰氨基)甲基取代了利奈唑胺的5-乙酰氨基甲基,这不利于抗菌活性。此外,与利奈唑胺和选择性抑制剂克罗吉林和Pargyline相比,5-(异羟肟酸)甲基恶唑烷酮衍生物作为MAO-A和-B抑制剂的活性也较低。通常,5-(异羟肟酸)甲基恶唑烷酮衍生物表现出中等但选择性的MAO-B抑制活性。 (C)2015 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号